These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29783490)

  • 1. HLA-B*5701 screening for hypersensitivity to abacavir.
    Faruki H; Lai-Goldman M
    Per Med; 2008 May; 5(3):297-300. PubMed ID: 29783490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA and drug-induced toxicity.
    Phillips EJ; Mallal SA
    Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
    Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
    AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
    Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
    Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno.
    Senatore C; Charlier B; Truono A; Punzi R; D'Aniello F; Boffa N; Izzo V; Conti V; Russomanno G; Manzo V; Filippelli A; Mazzeo M
    Transl Med UniSa; 2015; 11():55-8. PubMed ID: 25674551
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.